PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $200 | +21.2% | 18,873 | +4.4% | 0.00% | -50.0% |
| Q4 2023 | $165 | +31.0% | 18,070 | +48.6% | 0.00% | +100.0% |
| Q3 2023 | $126 | +55.6% | 12,164 | +7.4% | 0.00% | 0.0% |
| Q1 2023 | $81 | -100.0% | 11,328 | +34.5% | 0.00% | 0.0% |
| Q3 2021 | $270,000 | +39.9% | 8,420 | +43.7% | 0.00% | -50.0% |
| Q2 2020 | $193,000 | – | 5,858 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 5,827,415 | $197,258,000 | 18.19% |
| Abingworth LLP | 1,203,135 | $40,726,000 | 12.59% |
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $69,997,000 | 12.54% |
| Penn Mutual Asset Management | 86,940 | $2,943,000 | 3.68% |
| RA Capital Management | 3,115,008 | $105,443,000 | 1.69% |
| Greenspring Associates, LLC | 415,277 | $14,057,000 | 0.95% |
| Summit Rock Advisors, LP | 34,100 | $1,154,000 | 0.46% |
| Rhenman & Partners Asset Management AB | 186,210 | $6,303,000 | 0.43% |
| Ikarian Capital, LLC | 100,000 | $3,386,000 | 0.27% |
| Eventide Asset Management | 600,000 | $20,310,000 | 0.27% |